149 related articles for article (PubMed ID: 28628931)
1. [The Probabilistic Efficiency Frontier: A Value Assessment of Treatment Options in Hepatitis C].
Mühlbacher AC; Sadler A
Gesundheitswesen; 2019 Jan; 81(1):e21-e32. PubMed ID: 28628931
[TBL] [Abstract][Full Text] [Related]
2. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options.
Mühlbacher AC; Sadler A
Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207
[TBL] [Abstract][Full Text] [Related]
3. Cost Recommendation under Uncertainty in IQWiG's Efficiency Frontier Framework.
Corro Ramos I; Lhachimi SK; Gerber-Grote A; Al MJ
Med Decis Making; 2017 Feb; 37(2):162-172. PubMed ID: 27005521
[TBL] [Abstract][Full Text] [Related]
4. Determining the price for pharmaceuticals in Germany: comparing a shortcut for IQWiG's efficiency frontier method with the price set by the manufacturer for ticagrelor.
Gandjour A; Gafni A; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2014 Feb; 14(1):123-9. PubMed ID: 24354766
[TBL] [Abstract][Full Text] [Related]
5. Communicating the parameter uncertainty in the IQWiG efficiency frontier to decision-makers.
Stollenwerk B; Lhachimi SK; Briggs A; Fenwick E; Caro JJ; Siebert U; Danner M; Gerber-Grote A
Health Econ; 2015 Apr; 24(4):481-90. PubMed ID: 24590819
[TBL] [Abstract][Full Text] [Related]
6. The efficiency frontier approach to economic evaluation of health-care interventions.
Caro JJ; Nord E; Siebert U; McGuire A; McGregor M; Henry D; de Pouvourville G; Atella V; Kolominsky-Rabas P
Health Econ; 2010 Oct; 19(10):1117-27. PubMed ID: 20575151
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.
van der Pol S; de Jong LA; Vemer P; Jansen DEMC; Postma MJ
Value Health; 2019 Oct; 22(10):1119-1127. PubMed ID: 31563254
[TBL] [Abstract][Full Text] [Related]
8. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Grossi F; Costa F
Clin Ther; 2020 May; 42(5):830-847. PubMed ID: 32354495
[TBL] [Abstract][Full Text] [Related]
10. Decision making in Germany: is health economic evaluation as a supporting tool a sleeping beauty?
Gerber-Grote A; Sandmann FG; Zhou M; Ten Thoren C; Schwalm A; Weigel C; Balg C; Mensch A; Mostardt S; Seidl A; Lhachimi SK
Z Evid Fortbild Qual Gesundhwes; 2014; 108(7):390-6. PubMed ID: 25444297
[TBL] [Abstract][Full Text] [Related]
11. Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care.
Younossi ZM; Park H; Dieterich D; Saab S; Ahmed A; Gordon SC
Medicine (Baltimore); 2016 Oct; 95(41):e5048. PubMed ID: 27741116
[TBL] [Abstract][Full Text] [Related]
12. Cost-benefit evaluation of advanced therapy lines in metastatic triple-negative breast cancer in Germany.
Wickmann A; Kurte MS; Jeck J; Camacho L; Klinkhammer D; Kron F; Dengler R
Cost Eff Resour Alloc; 2024 Mar; 22(1):21. PubMed ID: 38459569
[TBL] [Abstract][Full Text] [Related]
13. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
14. Drug pricing and control of health expenditures: a comparison between a proportional decision rule and a cost-per-QALY rule.
Gandjour A
Int J Health Plann Manage; 2015; 30(4):395-402. PubMed ID: 24789123
[TBL] [Abstract][Full Text] [Related]
15. Early benefit assessment of pharmaceuticals in Germany: manufacturers' expectations versus the Federal Joint Committee's decisions.
Fischer KE; Stargardt T
Med Decis Making; 2014 Nov; 34(8):1030-47. PubMed ID: 25149822
[TBL] [Abstract][Full Text] [Related]
16. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
[TBL] [Abstract][Full Text] [Related]
17. Prices, Costs, and Affordability of New Medicines for Hepatitis C in 30 Countries: An Economic Analysis.
Iyengar S; Tay-Teo K; Vogler S; Beyer P; Wiktor S; de Joncheere K; Hill S
PLoS Med; 2016 May; 13(5):e1002032. PubMed ID: 27243629
[TBL] [Abstract][Full Text] [Related]
18. A theoretical and empirical investigation into the willingness-to-pay function for new innovative drugs by Germany's health technology assessment agency (IQWiG).
Gandjour A
Health Serv Manage Res; 2013 Nov; 26(4):103-9. PubMed ID: 25595007
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
20. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
Buyukkaramikli NC; Wigfield P; Hoang MT
Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
